News

Eli Lilly’s Mounjaro shows heart health benefits in head-to-head trial with older diabetes drug Trulicity
Eli Lilly said it believes the new data bolsters the case for Mounjaro to be prescribers' first choice for patients with Type ...
Eli Lilly Weight-Loss Drug Makes Cardio Advance. More Bad News for Novo Nordisk.
Eli Lilly drug Mounjaro resulted in a lower risk of heart attacks and strokes in patients with diabetes compared with the ...
Eli Lilly: The Best Growth Prospects Come At A Price
Eli Lilly's growth is fueled by GLP-1 blockbusters and a solid pipeline, yet high valuations and reliance on key drugs ...
Eli Lilly (LLY) Reports Results From SURPASS-CVOT Study: Mounjaro's Impact Analyzed
Eli Lilly (LLY) recently announced promising findings from its SURPASS-CVOT trial, revealing Mounjaro's potential benefits over Trulicity in reducing cardiovascular events. Despite these positive ...
Eli Lilly (LLY) Gets Price Target Boost as Analysts See Strong Mounjaro, Zepbound Sales
Eli Lilly & Company (NYSE:LLY) ranks among the best low volatility stocks to buy according to analysts. On July 11, ...
Devdiscourse3d
Blockbuster Diabetes Drugs Pioneer New Medical Frontiers
Diabetes drugs from Eli Lilly and Novo Nordisk, such as Mounjaro, Zepbound, Ozempic, and Wegovy, are expanding beyond ...
Why Eli Lilly Stock Was Looking Sickly Today
This peer was Novo Nordisk, which like Eli Lilly sells a popular drug approved specifically for obesity. Eli Lilly's recent ...
Fat jab wars wipe £70bn off Ozempic maker Novo Nordisk as it feels the heat from rival Eli Lilly
Shares in Novo Nordisk fell as much as 30% after it slashed sales and profits forecasts for the second time this year amid ...